Viracta Therapeutics, Inc. - Quarter Report: 2007 September (Form 10-Q)

---

---

---

 

R	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

£	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

Delaware		94-3295878
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification Number)

 

 

 

 

 

 

 

---

---

 

 

 

 

 

 

 

 

(1)	The condensed balance sheet at December 31, 2006 has been derived from the audited financial statements at that date included in the Company’s Form 10-K for the fiscal year ended December 31, 2006.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

·	the rate of progress and cost of our clinical trials, preclinical studies and other discovery and research and development activities;

·	the costs associated with establishing manufacturing and commercialization capabilities;

·	the costs of acquiring or investing in businesses, product candidates and technologies;

·	the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

·	the costs and timing of seeking and obtaining FDA and other regulatory approvals;

·	the effect of competing technological and market developments; and

·	the economic and other terms and timing of any collaboration, licensing or other arrangements into which we may enter.

 

 

 

 

 

 

·	fund clinical trials and seek regulatory approvals;

·	pursue the development of additional product candidates;

·	continue our research and expand our development activities;

·	build or access manufacturing and commercialization capabilities;

·	implement additional internal systems and infrastructure;

·	maintain, defend and expand the scope of our intellectual property portfolio; and

·	hire additional management and development personnel.

·	the rate of progress and cost of our clinical trials, preclinical studies and other discovery and research and development activities;

·	the economic and other terms and timing of any collaboration, licensing or other arrangements into which we may enter;

·	the costs associated with establishing manufacturing and commercialization capabilities;

·	the costs of acquiring or investing in businesses, product candidates and technologies;

·	the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

·	the costs and timing of seeking and obtaining FDA and other regulatory approvals; and

·	the effect of competing technological and market developments.

·	results from, and any delays in or discontinuance of, our clinical trial programs, including our ongoing and planned clinical trials for SNS-595, SNS-032 and SNS-314;

·	failure to raise additional capital to carry through with our clinical development plan;

·	announcements of FDA non-approval of our product candidates, including SNS-595, SNS-032 or SNS-314, delays in filing regulatory documents with the FDA or other regulatory agencies, or delays in the review process by the FDA or other foreign regulatory agencies;

·	failure or discontinuation of any of our research programs;

·	announcements relating to future collaborations or our existing collaborations with Biogen Idec, Johnson & Johnson PRD and Merck;

·	delays in the commercialization of our future products;

·	market conditions in the pharmaceutical, biopharmaceutical and biotechnology sectors and issuance of new or changed securities analysts’ reports or recommendations;

·	actual and anticipated fluctuations in our quarterly operating results;

·	developments or disputes concerning our intellectual property or other proprietary rights;

·	introduction of technological innovations or new products by us or our competitors;

·	issues in manufacturing or supplying the active ingredients for our product candidates or future products;

·	market acceptance of our future products;

·	deviations in our operating results from the estimates of analysts;

·	third-party healthcare reimbursement policies;

·	FDA or other U.S. or foreign regulatory actions affecting us or our industry;

·	litigation or public concern about the safety of our product candidates or future drugs;

·	sales of our common stock by our officers, directors or significant stockholders; and

·	additions or departures of key personnel.

 

*

The certifications attached as Exhibits 32.1 and 32.2 accompany this Quarterly Report on Form 10-Q, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Sunesis Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

 

 

		SUNESIS PHARMACEUTICALS, INC.
		(Registrant)
Date: November 8, 2007		/S/ ERIC H. BJERKHOLT
		Eric H. Bjerkholt Senior Vice President, Corporate Development and Finance, Chief Financial Officer

 

 

 

*

The certifications attached as Exhibits 32.1 and 32.2 accompany this Quarterly Report on Form 10-Q, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Sunesis Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.